BUSINESS
Business content
Post-Marketing Reevaluation Study
Release time:
2020-09-25 11:08
Source:
To effectively reduce drug safety risks, genuinely safeguard public medication safety, collect high-quality post-marketing data, promote further product development, obtain extensive usage data from large-scale populations, and guide clinical physicians in their prescribing practices.
Real-world research;
Pharmaco-economic evaluation;
Adverse reaction monitoring;
Drug lifecycle management;
Clinical and medical big data analytics and business strategies;
Business content
Recommended News
MA Achievement Release | Agomelatine Tablets Have Obtained Registration Approval!
Congratulations to Chongqing Huasen Pharmaceutical Co., Ltd. on obtaining the registration certificate for the agomelatine tablet project.
Starting November 1, 2024, applicants for marketing authorization of innovative drugs—as well as products that have been confirmed through communication and consultation to be eligible for the priority review and approval procedure and the conditional approval procedure—will receive early-stage acceptance services.
Follow us
Address: Room 3008, Building I, Yingkun Century, No. 6 Courtyard, East Road of the Automobile Museum, Fengtai District, Beijing
Phone: +86 10 86229816 Fax: 010-83739030
Email: bd-oyhz@healtech.com.cn (Business Cooperation)
ouyahuizhi-hr@healtech.com.cn (Resume Submission)
Follow the official account
WeChat Official Account
Friendship Links:Beijing Aotekang Pharmaceutical Technology Development Co., Ltd. Suzhou Suhao Biomaterials Technology Co., Ltd. Beijing Dikang Pharmaceutical Investment Management Co., Ltd. Center for Drug Evaluation, National Medical Products Administration National Medical Products Administration
Copyright © Eurasia Huizhi (Beijing) Medical Research Co., Ltd.